Formulation and Evaluation of Floating Drug Delivery System for Oxcarbazepine
Gunasekar Manoharan1*, Balaji Nagarajan1 and Bhargava Gottam2
1New Jersey Bioscience Centre, New Jersey, USA
2Harrisburg University of Science and Technology, Pennsylvania, USA
*Corresponding Author: Gunasekar Manoharan, New Jersey Bioscience Centre, New Jersey, USA.
December 10, 2021; Published: December 27, 2021
Sustained release tablets of oxcarbazepine that float, erode and diffuse were prepared using various hydrophilic polymers. The buoyancy of the tablets was achieved by incorporation of the gas-generating agent sodium bicarbonate. The effect of various parameters on buoyancy and release profile was investigated. The tablets became buoyant within minutes and floated for more than 12 hours in vitro with good integrity and released more than 90% of the drug. The tablets exhibited prolonged floating properties due to low density polymers and formation of CO2 by a gas generating material. A zero-order drug release involving swelling and erosion of the system was observed. This study shows that tablet composition and mechanical strength have the greatest influence on the floating properties and sustained drug release. The system was shown to have an excellent floating ability and sustained release characteristics in vitro, irrespective of pH. The floating dosage form was found to be a feasible approach in delivering oxcarbazepine to the upper GIT to maximize drug absorption.
Keywords: Oxcarbazepine; Floating Tablets; HPMC K 4M; HPMC K 15M
- Goodman and Gillman-Drugs effective in the treatment of the epilepsies in the pharmacological basis of therapeutics. Mc Graw Hill, New York.
- Deshpande A., et al. “Controlled-release drug delivery systems for prolonged gastric residence: an overview”. Drug Development and Industrial Pharmacy6 (1996): 531-539.
- Deshpande A., et al. “Development of a novel controlled-release system for gastric retention”. Pharmaceutical Research 6 (1997): 815-819.
- Buri P., et al. “Formes pharmaceutiques nouvelles, Technique et Documentation”. Lavoisier (1985): 201-212.
- Sheth P., et al. “The hydrodynamically balanced system (HBSTM): A novel drug delivery system for oral use”. Drug Development and Industrial Pharmacy 2 (1984): 313-339.
- Watanabe S., et al. “Solid therapeutic preparation remaining in stomach”. U.S. Patent 3976764 (1976).
- Mitra S B. “Polymers as biomaterials (Shalaby S. W., Hoffman A. S., Ratner B.D., Horbett T. A., eds)”. (1984):
- B. C., et al. “Oral sustained-release drug delivery systems using polycarbonate microspheres capable of floating on the gastric fluid”. Journal of Pharmacy and Pharmacology 45 (1993): 21-24.
- Bolton S., et al. “Floating sustained release therapeutic compositions”. U.S. Patent 4814179, (1989).
- Ichikawa M., et al. “A new multiple-unit oral floating system I: Preparation and in vitro evaluation of floating and sustained-release characteristics”. Journal of Pharmaceutical Sciences 80 (1991): 1062-1066.
- Ichikawa M., et al. “Granule remaining in stomach”. US Patent 4,844,905, (1989).
- Nakamichi K., et al. “Gastric remaining preparation, swollen molding, and production process”. EP 0 717 988, 26 (1996).
- Choi B Y., et al. “Preparation of alginate beads for floating drug delivery system: effects of carbon dioxide forming agents”. International Journal of Pharmaceutics 239 (2002): 81-91.
- Nur AO., et al. “Captopril floating and/or bioadhesive tablets: Design and release kinetics”. Drug Development and Industrial Pharmacy 9 (2000): 965-969.
- Nei Z., et al. “Design and evaluation of a two-layer floating tablet for gastric retention using cisapride as a model drug”. Drug Development and Industrial Pharmacy 5 (2001): 469-474.
- Hilton A K., et al. “Invitro and In-vivo evaluation of an oral sustained-release floating dosage form of amoxycillin trihydrate”. International Journal of Pharmaceutics 86 (1992): 79-88.
- Sas A., et al. “Optimization of floating matrix tablets and evaluation of their gastric residence time”. International Journal of Pharmaceutics 195 (2000): 125-135.
- Rouge N., et al. “Buoyancy and drug release patterns of floating minitablets containing Piretanide and Atenolol as model drugs”. Pharmaceutical Development and Technology 3 (1998): 73-84.
- Timmermans J., et al. “How well do floating dosage forms float”. International Journal of Pharmaceutics 62 (1990): 207-216.